Sutro Biopharma/STRO

$4.80

6.3%
-
1D1W1MYTD1YMAX

About Sutro Biopharma

Sutro Biopharma, Inc. is a clinical-stage oncology company. The Company is engaged in developing site-specific and novel-format antibody drug conjugates (ADCs) enabled by its integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. It provides two wholly owned ADCs in the clinic, namely luveltamab tazevibulin (STRO-002 or luvelta) and STRO-001. STRO-002 is an ADC directed against folate receptor-alpha (FolRa) for patients with FolRa-expressing cancers, including ovarian cancer. In addition, it uses luvelta to treat pediatric patients with relapsed/refractory CBFA2T3-GLIS2 and acute myeloid leukemia. STRO-001 is an ADC directed against CD74, for patients with B-cell malignancies, such as multiple myeloma and non-Hodgkin lymphoma (NHL). Its preclinical product candidate, STRO-003, is a single homogeneous ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1), developed for the treatment of solid tumors.

Ticker

STRO

Sector

Tervishoid

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

William Newell

Employees

298

Headquarters

South san francisco, United States

Sutro Biopharma Metrics

BasicAdvanced
$275.51M
Market cap
-
P/E ratio
-$2.91
EPS
0.93
Beta
-
Dividend rate

What the Analysts think about Sutro Biopharma

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 9 analysts.
205.63% upside
High $25.00
Low $8.00
$4.80
Current price
$14.67
Average price target

Sutro Biopharma Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-291.12% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$16.9M
62.5%
Net income
$-49.2M
27.79%
Profit margin
-291.12%
-21.36%

Sutro Biopharma Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 10.05%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.68
-$0.85
-$0.64
-$0.81
-
Expected
-$0.62
-$0.81
-$0.73
-$0.74
-$0.82
Surprise
9.46%
4.75%
-12.63%
10.05%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Sutro Biopharma stock

Buy or sell Sutro Biopharma stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing